BofA Lifts PT on Johnson & Johnson (JNJ) to $227 From $221 - Here's Why

Johnson & Johnson (NYSE:JNJ) is one of the best long term low volatility stocks to invest in. On January 30, BofA lifted the price target on Johnson & Johnson (NYSE:JNJ) to $227 from $221 while maintaining a Neutral rating on the shares. The firm told investors that the increased price target points towards a higher blended P/E multiple, which in turn assumes a raised MedTech multiple on a  higher Pharma multiple and higher organic growth, given a defensive premium.

BofA added that a Daubert ruling in the talc MDL case may be issued in the upcoming 1-2 months. However, it stated that the outcome of any legal case is “inherently unpredictable”, and that includes any potential settlement or injunction. The firm believes the talc risk to be manageable, as even a mid-teens billion resolution cost is less than 3% of the company’s market cap.

In a separate development, Johnson & Johnson (NYSE:JNJ) announced on January 27 the FDA approval of DARZALEX FASPRO® in combination with bortezomib, lenalidomide, and dexamethasone to treat adult patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant. Regardless of transplant eligibility, D-VRd is the only anti-CD38 antibody-based regimen with approved indications across newly diagnosed patients.

Management added that the FDA approval marks the twelfth indication for DARZALEX FASPRO® and fifth in the newly diagnosed setting, highlighting its significant role as a foundational therapy for both newly diagnosed and relapsed/refractory multiple myeloma patients.

Johnson & Johnson (NYSE:JNJ) develops, manufactures, and sells products in the healthcare field. The company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment focuses on various therapeutic areas, including oncology, infectious diseases, immunology, cardiovascular and metabolic diseases, and others. The MedTech segment includes an elaborate range of medical devices and products used in cardiovascular intervention, orthopedics, interventional solutions, surgery, and vision fields.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.